At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03378 HANXBIO-B
Market Closed 06-12 16:08:19
26.860
+0.060
+0.22%
High27.500Low25.540Vol109.70K
Open27.700D1 Closing26.800Amplitude7.31%
Mkt Cap3.63BTradable Cap3.63BTotal Shares135.00M
T/O2.90MT/O Rate0.08%Tradable Shares135.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares
Bulletin Express  ·  06-12 19:43
Hanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares
HANXBIO-B Buys Back 41,800 Shares for HK$1.122 Million on June 12
Stock News  ·  06-12 19:30
HANXBIO-B Buys Back 41,800 Shares for HK$1.122 Million on June 12
Hanx Biopharma files HKEX next-day disclosure return on share repurchase at HKD 26-27.7
Reuters  ·  06-12 19:25
Hanx Biopharma files HKEX next-day disclosure return on share repurchase at HKD 26-27.7
HANXBIO-B Repurchases 33,100 Shares for HK$876,000 on June 11
Stock News  ·  06-11 19:14
HANXBIO-B Repurchases 33,100 Shares for HK$876,000 on June 11
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share buyback at HKD 26.47 each
Reuters  ·  06-11 19:10
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share buyback at HKD 26.47 each
HANXBIO-B repurchases 68,800 H shares for HKD 1.82 million
Bulletin Express  ·  06-09
HANXBIO-B repurchases 68,800 H shares for HKD 1.82 million
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share buyback cancellation
Reuters  ·  06-09
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share buyback cancellation
HANXBIO-B Allocates HK$1.6785 Million for Share Buyback on June 8
Stock News  ·  06-08
HANXBIO-B Allocates HK$1.6785 Million for Share Buyback on June 8
Hanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million
Bulletin Express  ·  06-05
Hanx Bio repurchases 0.04 million H shares at up to HKD 27.98, expands treasury stock to 1.04 million
HANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares
Bulletin Express  ·  06-04
HANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares
HANXBIO-B Executes Share Buyback, Spending HK$765,400
Stock News  ·  06-04
HANXBIO-B Executes Share Buyback, Spending HK$765,400
Hanx Biopharma files HKEX next-day return disclosing share buyback at HKD 27.63 each
Reuters  ·  06-04
Hanx Biopharma files HKEX next-day return disclosing share buyback at HKD 27.63 each
HANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%
Bulletin Express  ·  06-03
HANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%
HANXBIO-B Executes Share Buyback Valued at Approximately HK$1.44 Million
Stock News  ·  06-03
HANXBIO-B Executes Share Buyback Valued at Approximately HK$1.44 Million
HANXBIO-B buys back 405,800 H-shares in May, spending HKD 12.08 million while maintaining public float
Bulletin Express  ·  06-03
HANXBIO-B buys back 405,800 H-shares in May, spending HKD 12.08 million while maintaining public float
Hanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital
Bulletin Express  ·  06-02
Hanx Biopharmaceuticals repurchases HKD 1.07 million of H-shares; treasury stock climbs to 0.68 % of total issued capital
Hanx Biopharmaceuticals Calls 24 Jun 2026 AGM to Vote on 2025 Results, 20% Issuance Mandate and 10% H-Share Buyback
Bulletin Express  ·  06-02
Hanx Biopharmaceuticals Calls 24 Jun 2026 AGM to Vote on 2025 Results, 20% Issuance Mandate and 10% H-Share Buyback
Hanx Biopharmaceuticals to Seek 20% Issuance, 10% Buy-back Mandates and Expand Business Scope
Bulletin Express  ·  06-02
Hanx Biopharmaceuticals to Seek 20% Issuance, 10% Buy-back Mandates and Expand Business Scope
Hanx Biopharmaceuticals Relocates Hong Kong Principal Office to Lee Garden One
Bulletin Express  ·  06-02
Hanx Biopharmaceuticals Relocates Hong Kong Principal Office to Lee Garden One
Hanx Biopharmaceuticals relocates Hong Kong principal office to Lee Garden One, Causeway Bay
Reuters  ·  06-02
Hanx Biopharmaceuticals relocates Hong Kong principal office to Lee Garden One, Causeway Bay

Introduction

Company Name.
HANXBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.
Issue price:
--